Plant Comparison

Horse Chestnut vs Witch Hazel

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant AHorse ChestnutAesculus hippocastanumSapindaceaeFull monograph →
Plant BWitch HazelHamamelis virginianaHamamelidaceaeFull monograph →

At a glance

Horse Chestnut and Witch Hazel: they share 5 indicated uses (arthritis / joint pain, cancer (anticancer research), haemorrhoids, …); 2 pharmacological actions in common.

Horse ChestnutWitch Hazel
Constituents22
Pharmacological actions45
Indicated uses89
Safety notes22
Cited sources1916
Indicated uses
Only Horse Chestnut
Pain (general)Swelling / fluid retentionVaricose veins
Shared (5)
Arthritis / joint painCancer (anticancer research)HaemorrhoidsInflammation (general)Skin irritation
Only Witch Hazel
BruisingDiarrhoeaOral & throat healthWounds
Pharmacological actions
Only Horse Chestnut
Anti-oedematous (reduces swelling)Venotonic / vasoprotective
Shared (2)
Anti-inflammatoryAnticancer (preclinical)
Only Witch Hazel
AntioxidantAstringentVulnerary (wound healing)

Evidence face-off — shared uses

ConditionHorse ChestnutWitch HazelVerdict
Arthritis / joint pain2/105/10Stronger for Witch Hazel
Cancer (anticancer research)2/102/10Comparable evidence
Haemorrhoids2/101/10Comparable evidence
Inflammation (general)2/105/10Stronger for Witch Hazel
Skin irritation2/105/10Stronger for Witch Hazel

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Triterpene saponins (escin / aescin)[1, 6, 7, 8, 9]

The active mixture responsible for the venotonic and anti-oedematous effects; extracts are standardised to it. Escin is available as oral drages and a transdermal gel, with efficacy shown in chronic venous insufficiency and blunt-trauma injury.

Triterpene saponinsTerpenes / terpenoidsSaponinsEscin (aescin)
Flavonoids and coumarins (aesculin)[5, 6]

Supporting constituents of the seed.

FlavonoidsCoumarins
Tannins (4-10%, including hamamelitannin and gallotannins)[14, 15]

The principal astringent and anti-inflammatory constituents.

Tannins
Flavonoids, catechins, proanthocyanidins and phenolic acids[15]

Antioxidant and anti-inflammatory constituents of the bark and leaf.

ProanthocyanidinsPhenolic acidsFlavonoidsCatechins

Pharmacological Actions

Anti-inflammatory[1, 2, 4, 8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins

Anti-oedematous (reduces swelling)[8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins

Anticancer (preclinical)[6, 11, 12, 13, 14, 15]

Escin, the triterpene saponin of Aesculus hippocastanum, induces apoptosis and cell-cycle arrest and chemosensitizes breast, hepatocellular, lung and pancreatic cancer cells (preclinical, including in vivo xenograft models).

Venotonic / vasoprotective[1, 8]

Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins; Relief of haemorrhoid symptoms (venotonic)

Anti-inflammatory[2, 4, 5, 6, 14, 15, 16]

Anti-inflammatory and antioxidant (supports irritated/atopic skin); Relief of haemorrhoid symptoms (astringent and anti-inflammatory)

Anticancer (preclinical)[11]
Antioxidant[2, 15]

Anti-inflammatory and antioxidant (supports irritated/atopic skin)

Astringent[6, 8, 9, 14, 15, 16]

Astringent for skin irritation and minor inflammation of the skin and oral mucosa (tannins), applied topically; Relief of haemorrhoid symptoms (astringent and anti-inflammatory)

Vulnerary (wound healing)[7, 14, 16]

Vulnerary for minor wounds, bruises and insect bites

Traditional & Indicated Uses

Arthritis / joint pain[4, 6, 8, 11, 16]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Arthritis / joint pain
Cancer (anticancer research)[6, 11, 12, 13, 14, 15]Traditional · 2/10

Escin shows antiproliferative and pro-apoptotic activity and enhances chemotherapy/immunotherapy efficacy in breast (MCF-7), hepatocellular, lung and pancreatic cancer models; it modulates NF-kappaB, p53, p38 MAPK/ERK and PD-L1 (preclinical).

Evidence: 2
Label: Cancer (anticancer research)
Haemorrhoids[8]Traditional · 2/10

Relief of haemorrhoid symptoms (venotonic)

Evidence: 2
Label: Haemorrhoids
Inflammation (general)[6, 8, 11, 16]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Inflammation (general)
Pain (general)[7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Pain (general)
Skin irritation[8]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Skin irritation
Swelling / fluid retention[7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Swelling / fluid retention
Varicose veins[5, 7, 17, 18]Good · 7/10

Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins

Evidence: 7
Label: Varicose veins
Arthritis / joint pain[14, 15, 16]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Arthritis / joint pain
Bruising[14, 16]Traditional · 1/10

Vulnerary for minor wounds, bruises and insect bites

Evidence: 1
Label: Bruising
Cancer (anticancer research)[11]Traditional · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Diarrhoea[14, 15, 16]Moderate · 5/10

inferred from astringent action

Evidence: 5
Label: Diarrhoea
Haemorrhoids[14, 16]Traditional · 1/10

Relief of haemorrhoid symptoms (astringent and anti-inflammatory)

Evidence: 1
Label: Haemorrhoids
Inflammation (general)[14, 15]Moderate · 5/10

Astringent for skin irritation and minor inflammation of the skin and oral mucosa (tannins), applied topically

Evidence: 5
Label: Inflammation (general)
Oral & throat health[14, 15]Moderate · 5/10

Astringent for skin irritation and minor inflammation of the skin and oral mucosa (tannins), applied topically

Evidence: 5
Label: Oral & throat health
Skin irritation[14, 15]Moderate · 5/10

Astringent for skin irritation and minor inflammation of the skin and oral mucosa (tannins), applied topically

Evidence: 5
Label: Skin irritation
Wounds[14, 16]Traditional · 1/10

Vulnerary for minor wounds, bruises and insect bites

Evidence: 1
Label: Wounds

Safety, Cautions & Contraindications

Safety note[7]Info

Use only standardised, processed seed extract. Raw conkers, leaves and bark contain toxic esculin and can cause poisoning - never eat raw horse chestnut.

Safety note[7]Caution

May increase bleeding risk, so use caution with anticoagulant/antiplatelet medicines; use caution in kidney disease and avoid in pregnancy and breastfeeding.

Safety note[16]Caution

For topical use. Do not apply to deep wounds, serious burns or severe rectal bleeding - these need medical care.

Safety note[15, 16]Caution

Oral use is not recommended in pregnancy or breastfeeding without professional guidance, and swallowing tannin-rich preparations can upset the stomach. Mild skin irritation or contact allergy is possible.

External Ids

Gbif: 3189815
Wikidata: Q26899
Gbif: 3152827
Powo: urn:lsid:ipni.org:names:430697-1
Wikidata: Q913129

Botanical Description

Large deciduous tree, to 25-30 m, with a broad domed crown and stout, upward-arching branches. The leaves are opposite and palmately compound, with five to seven large, obovate, toothed leaflets radiating from a long stalk. In spring the tree bears large, showy, upright pyramidal flower spikes ('candles') of white flowers marked with yellow or pink at the base. The glossy brown seeds ('conkers') develop inside a spiky green husk and fall in autumn.[1]

Height: Up to 25-30 m
Habit: Large deciduous tree
Leaves: Opposite, palmately compound with 5-7 large obovate toothed leaflets
Flowers: Showy, upright, pyramidal spikes ('candles') of white flowers marked yellow/pink at the base
Stem: Stout trunk with a broad domed crown of upward-arching branches
Root: Not medicinally used
Fruit: Glossy brown seed ('conker') enclosed in a spiny green husk
Flowering Period: April-May

Large, multi-stemmed deciduous shrub or small tree with broad, oval, wavy-toothed leaves, asymmetrical at the base. Unusually, it flowers in late autumn to winter after the leaves have fallen, bearing clusters of small, spidery, bright yellow flowers with narrow, crinkled, ribbon-like petals. The woody seed capsule matures the following autumn and explosively ejects its seeds ('snapping hazelnut').[14]

Height: 3-8 m
Habit: Large, multi-stemmed deciduous shrub or small tree
Leaves: Broad, oval, wavy-toothed, asymmetrical at the base
Flowers: Small, spidery, bright yellow, with narrow crinkled ribbon-like petals, blooming in late autumn/winter
Stem: Multiple woody stems with smooth, grey-brown bark
Root: Woody root system
Fruit: Woody capsule maturing the following autumn, explosively ejecting seeds
Flowering Period: October-December (after leaf-fall)

Habitat

Native to the Balkan Peninsula, and widely planted and naturalised as an ornamental and avenue tree across temperate Europe, North America and elsewhere.[1]

Native to woodland understorey and forest margins of eastern North America; widely cultivated as an ornamental and medicinal shrub.[14]

Harvesting

The seeds are gathered as they fall from the spiny husks in autumn; medicinal use requires a standardised, processed extract, since the raw seed, bark and leaves contain toxic esculin and must never be eaten raw.[1, 7]

Parts: Seed (standardised extract)
Season: Autumn

Bark is stripped from branches (not the main trunk, to avoid harming the plant) and leaves are picked in summer; both are dried for use, or steam-distilled together with twigs to produce distilled witch-hazel water, the most common commercial form.[14]

Parts: Bark, leaf and distilled witch-hazel water
Season: Bark and leaf in summer

Traditional Uses

Horse chestnut seed has a long folk history as a remedy for varicose veins, haemorrhoids and 'heavy legs', and was also used topically for rheumatic pain and bruising. Modern use is almost exclusively as a standardised seed extract for chronic venous insufficiency, confirming this traditional venous-support reputation.[1]

Witch hazel has a long Native American and, after adoption by European settlers, worldwide reputation as a topical astringent and anti-inflammatory remedy for skin irritation, minor wounds, bruises, insect bites and haemorrhoids, and as a soothing wash for irritated skin and mucous membranes.[14]

Preparations

Standardised extract (oral)[1, 8]

Standardised seed extract, normalised to escin content, taken as tablets or capsules for chronic venous insufficiency; this is the best-studied clinical form.

Topical gel[8]

Escin-containing transdermal gel applied to the skin over affected veins or bruised tissue.

Distilled witch-hazel water[14]

Steam-distilled preparation of the bark and twigs, applied topically as a soothing, astringent skin toner and wound wash; the most widely used commercial form.

Decoction (bark/leaf)[14]

Dried bark or leaf simmered in water and used as a cooled topical wash or compress.

Dosage

Standardised oral extract[8]

Clinical studies commonly use extracts standardised to around 100-150 mg escin daily, in divided doses. Educational reference only, not a prescription.

Topical gel[10]

The EU herbal monograph gives semi-solid dosage forms containing the equivalent of 0.4% triterpene glycosides calculated as protoaescigenin (or, depending on the preparation, 0.85-20% herbal preparation), applied as a thin layer to the affected area 1-3 times daily, in adults and elderly. Educational reference only, not a prescription.

Topical preparations[14]

The EU herbal monograph on Hamamelis virginiana L., cortex gives, for cutaneous use, tincture at a strength corresponding to 5-10% in semi-solid preparations several times daily, or a dry extract (5-7.7:1, ethanol 30% m/m) at a strength corresponding to 1.3% as an ointment several times daily; for anorectal use, a decoction of 5-10 g per 250 mL up to 3 times daily as impregnated dressings. For topical use only. Educational reference only, not a prescription.

References

REF-2402, REF-2403, REF-2404, REF-2405, REF-2406
REF-0830, REF-0831, REF-0832, REF-2049, REF-2050, REF-2051, REF-2052, REF-2053, REF-2054, REF-2055, REF-2056, REF-2057, REF-2058

Drug Class Interactions

Safety note[19]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: Horse chestnut seed contains aescin and coumarin-like constituents (esculin) that may add to the effect of blood-thinning or antiplatelet drugs, so combined use should be monitored.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Idris, S. and Mishra, A. and Khushtar, M (2020) 'Phytochemical, ethnomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine', Journal of Basic and Clinical Physiology and Pharmacology, 31(5). doi:10.1515/jbcpp-2019-0115 Meta-analysis / review
    https://doi.org/10.1515/jbcpp-2019-0115
  2. Penaranda Figueredo, F.A. and Vicente, J. and Barquero, A.A. and Bueno, C.A (2024) 'Aesculus hippocastanum extract and the main bioactive constituent beta-escin as antivirals agents against coronaviruses, including SARS-CoV-2', Scientific Reports, 14(1), pp. 6418. doi:10.1038/s41598-024-56759-y Preclinical
    https://doi.org/10.1038/s41598-024-56759-y
  3. Idris, S. and Mishra, A. and Khushtar, M (2023) 'Phytochemical Estimation and Therapeutic Amelioration of Aesculus hippocastanum L. Seeds Ethanolic Extract in Gastric Ulcer in Rats Possibly by Inhibiting Prostaglandin Synthesis', Chinese Journal of Integrative Medicine, 29(9), pp. 818-824. doi:10.1007/s11655-023-3734-9 Preclinical
    https://doi.org/10.1007/s11655-023-3734-9
  4. Quarta, S. and Santarpino, G. and Carluccio, M.A. and Calabriso, N. and Scoditti, E. and Siculella, L. and Damiano, F. and Maffia, M. and Verri, T. and De Caterina, R. and Massaro, M (2022) 'Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat Fast, a Combination of Plant Extracts, Bromelain and Escin (Aesculus hippocastanum), Evaluated in In Vitro Models of Inflammation Relevant to Osteoarthritis', Pharmaceuticals, 15(10), pp. 1263. doi:10.3390/ph15101263 Preclinical
    https://doi.org/10.3390/ph15101263
  5. Owczarek, A. and Kolodziejczyk-Czepas, J. and Wozniak-Serwata, J. and Magiera, A. and Kobiela, N. and Wasowicz, K. and Olszewska, M.A (2021) 'Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models', Antioxidants, 10(7), pp. 995. doi:10.3390/antiox10070995 Preclinical
    https://doi.org/10.3390/antiox10070995
  6. Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters. doi:10.1016/j.canlet.2018.02.027 Preclinical
    https://doi.org/10.1016/j.canlet.2018.02.027
  7. Pittler, M.H. and Ernst, E (2012) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003230.pub4 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD003230.pub4
  8. Gallelli, L (2019) 'Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties', Drug Design, Development and Therapy, pp. 3425--3437. doi:10.2147/DDDT.S207720 Preclinical
    https://doi.org/10.2147/DDDT.S207720
  9. Wu, X.J., Zhang, M.L., Cui, X.Y., Gao, F., He, Q., Li, X.J., Zhang, J.W., Fawcett, J.P. and Gu, J.K (2011) 'Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat', Journal of Ethnopharmacology, 139(1), pp. 201--206. doi:10.1016/j.jep.2011.11.003 Preclinical
    https://doi.org/10.1016/j.jep.2011.11.003
  10. European Medicines Agency (HMPC) (2023) 'European Union herbal monograph on Aesculus hippocastanum L., semen, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf Traditional / reference
    https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf
  11. Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters, pp. 1--8. doi:10.1016/j.canlet.2018.02.027 Preclinical
    https://doi.org/10.1016/j.canlet.2018.02.027
  12. Mazrouei, R. and Raeisi, E. and Lemoigne, Y. and Heidarian, E (2019) 'Activation of p53 Gene Expression and Synergistic Antiproliferative Effects of 5-Fluorouracil and beta-escin on MCF7 Cells', Journal of Medical Signals and Sensors, 9(3), pp. 196-203. doi:10.4103/jmss.JMSS_44_18 Preclinical
    https://doi.org/10.4103/jmss.JMSS_44_18
  13. Yuan, Y. and Wang, P. and Chen, S. and Cao, Z. and Ojha, S.C. and Sun, C. and Wang, G. and Wang, Z. and Gu, J. and Kang, J. and Xue, X (2025) 'Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma', Phytomedicine, 149, pp. 157532. doi:10.1016/j.phymed.2025.157532 Preclinical
    https://doi.org/10.1016/j.phymed.2025.157532
  14. Hussain, Y. and Singh, J. and Meena, A. and Sinha, R.A. and Luqman, S (2023) 'Escin enhanced the efficacy of sorafenib by autophagy-mediated apoptosis in lung cancer cells', Phytotherapy Research, 37(10), pp. 4819-4837. doi:10.1002/ptr.7948 Preclinical
    https://doi.org/10.1002/ptr.7948
  15. Rimmon, A. and Vexler, A. and Berkovich, L. and Earon, G. and Ron, I. and Lev-Ari, S (2013) 'Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway', Biochemistry Research International, 2013, pp. 251752. doi:10.1155/2013/251752 Preclinical
    https://doi.org/10.1155/2013/251752
  16. Domanski, D., Zegrocka-Stendel, O., Perzanowska, A., Dutkiewicz, M., Kowalewska, M., Grabowska, I., Maciejko, D., Fogtman, A., Dadlez, M. and Koziak, K (2016) 'Molecular Mechanism for Cellular Response to beta-Escin and Its Therapeutic Implications', PLoS One, 11(10). doi:10.1371/journal.pone.0164365 Preclinical
    https://doi.org/10.1371/journal.pone.0164365
  17. Gloviczki, M.L., Kakkos, S.K., Urbanek, T., Chuback, J. and Nicolaides, A (2025) 'The role of venoactive compounds in the treatment of chronic venous disease', Journal of Vascular Surgery: Venous and Lymphatic Disorders, 13(5). doi:10.1016/j.jvsv.2025.102258 Preclinical
    https://doi.org/10.1016/j.jvsv.2025.102258
  18. Santiago, F.R., Grillo, L., Amore, M., Carmelino, C., Trejo, J.M.R. and Ulloa, J.H (2026) 'Venoactive drugs in the management of chronic venous disease: A critical appraisal of the evidence and comparison with international guidelines', Vascular Pharmacology. doi:10.1016/j.vph.2026.107614 Preclinical
    https://doi.org/10.1016/j.vph.2026.107614
  19. Pittler, M.H. and Ernst, E (2006) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews, 2006(1), pp. CD003230. doi:10.1002/14651858.CD003230.pub3 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD003230.pub3
  1. Skowrońska, W., Pawłowska, K.A., Obrębski, M., Piwowarski, J.P. et al (2025) 'Chemical composition, skin microbiota metabolism, antimicrobial potential and anti-inflammatory properties of witch hazel bark (Hamamelis virginiana L.)', Journal of Ethnopharmacology, 353(Pt B), pp. 120433. doi:10.1016/j.jep.2025.120433 Preclinical
    https://doi.org/10.1016/j.jep.2025.120433
  2. Piazza, S., Martinelli, G., Vrhovsek, U., Masuero, D. et al (2022) 'Anti-Inflammatory and Anti-Acne Effects of Hamamelis virginiana Bark in Human Keratinocytes', Antioxidants (Basel), 11(6), pp. 1119. doi:10.3390/antiox11061119 Preclinical
    https://doi.org/10.3390/antiox11061119
  3. Janarthanam, V.A., Rajan, P.S.S., Panda, S.P., Panigrahy, U.P. et al (2025) 'Hamamelitannin from Hamamelis virginiana Attenuates Ethanol-Induced Oxidative and Inflammatory Responses in Danio rerio Larvae', Molecular Biotechnology, 68(5), pp. 2369-2385. doi:10.1007/s12033-025-01502-9 Preclinical
    https://doi.org/10.1007/s12033-025-01502-9
  4. Piazza, S., Martinelli, G., Magnavacca, A., Fumagalli, M., Pozzoli, C., Terno, M., Canilli, L., Angarano, M., Maranta, N., Dell'Agli, M. and Sangiovanni, E (2022) 'Unveiling the Ability of Witch Hazel (Hamamelis virginiana L.) Bark Extract to Impair Keratinocyte Inflammatory Cascade Typical of Atopic Eczema', International Journal of Molecular Sciences, 23(16), pp. 9279. doi:10.3390/ijms23169279 Preclinical
    https://doi.org/10.3390/ijms23169279
  5. Amendola, I., Viegas, D.J., Freitas, E.T., Oliveira, J.R., Santos, J.G., Oliveira, F.E., Lagareiro Netto, A.A., Marcucci, M.C., Oliveira, L.D. and Back-Brito, G.N (2024) 'Hamamelis virginiana L. extract presents antimicrobial and antibiofilm effects, absence of cytotoxicity, anti-inflammatory action, and potential to fight infections through the nitric oxide production by macrophages', Anais da Academia Brasileira de Ciencias, 96(1), pp. e20200031. doi:10.1590/0001-3765202320200031 Preclinical
    https://doi.org/10.1590/0001-3765202320200031
  6. Habtemariam, S (2002) 'Hamamelitannin from Hamamelis virginiana inhibits the tumour necrosis factor-alpha (TNF)-induced endothelial cell death in vitro', Toxicon, 40(1), pp. 83-88. doi:10.1016/s0041-0101(01)00195-7 Preclinical
    https://doi.org/10.1016/s0041-0101(01)00195-7
  7. Natella, F., Guantario, B., Ambra, R., Ranaldi, G., Intorre, F., Burki, C. and Canali, R (2021) 'Human Metabolites of Hamamelis virginiana (Extract) Modulate Fibroblast Extracellular Matrix Components in Response to UV-A Irradiation', Frontiers in Pharmacology, 12, pp. 747638. doi:10.3389/fphar.2021.747638 Randomized trial
    https://doi.org/10.3389/fphar.2021.747638
  8. Dauer, A., Rimpler, H. and Hensel, A (2003) 'Polymeric proanthocyanidins from the bark of Hamamelis virginiana', Planta Medica, 69(1), pp. 89-91. doi:10.1055/s-2003-37022 Preclinical
    https://doi.org/10.1055/s-2003-37022
  9. Vennat, B., Pourrat, H., Pouget, M.P., Gross, D. and Pourrat, A (1988) 'Tannins from Hamamelis virginiana: identification of proanthocyanidins and hamamelitannin quantification in leaf, bark, and stem extracts', Planta Medica, 54(5), pp. 454-457. doi:10.1055/s-2006-962499 Preclinical
    https://doi.org/10.1055/s-2006-962499
  10. Duckstein, S.M., Lorenz, P. and Stintzing, F.C (2012) 'Conversion of phenolic constituents in aqueous Hamamelis virginiana leaf extracts during fermentation', Phytochemical Analysis, 23(6), pp. 588-597. doi:10.1002/pca.2359 Preclinical
    https://doi.org/10.1002/pca.2359
  11. Sanchez-Tena, S., Fernandez-Cachon, M.L., Carreras, A., Mateos-Martin, M.L., Costoya, N., Moyer, M.P., Nunez, M.J., Torres, J.L. and Cascante, M (2012) 'Hamamelitannin from witch hazel (Hamamelis virginiana) displays specific cytotoxic activity against colon cancer cells', Journal of Natural Products, 75(1), pp. 26-33. doi:10.1021/np200426k Preclinical
    https://doi.org/10.1021/np200426k
  12. Theisen, L.L., Erdelmeier, C.A.J., Spoden, G.A., Boukhallouk, F., Sausy, A., Florin, L. and Muller, C.P (2014) 'Tannins from Hamamelis virginiana bark extract: characterization and improvement of the antiviral efficacy against influenza A virus and human papillomavirus', PLoS One, 9(1), pp. e88062. doi:10.1371/journal.pone.0088062 Preclinical
    https://doi.org/10.1371/journal.pone.0088062
  13. Cheesman, M.J., Alcorn, S.R., White, A. and Cock, I.E (2023) 'Hamamelis virginiana L. Leaf Extracts Inhibit the Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria', Antibiotics, 12(7), pp. 1195. doi:10.3390/antibiotics12071195 Preclinical
    https://doi.org/10.3390/antibiotics12071195
  14. European Medicines Agency (HMPC) (n.d.) 'European Union herbal monograph on Hamamelis virginiana L., cortex/folium/aqua (Hamamelidis cortex)'. Available at: https://www.ema.europa.eu/en/medicines/herbal/hamamelidis-cortex Traditional / reference
    https://www.ema.europa.eu/en/medicines/herbal/hamamelidis-cortex
  15. (2025) 'Hamamelis virginiana L. in Skin Care: A Review of Its Pharmacological Properties and Cosmetological Applications', Molecules. doi:10.3390/molecules30132744 Randomized trial
    https://doi.org/10.3390/molecules30132744
  16. Herbal Reality (n.d.) 'Witch Hazel (Hamamelis virginiana): Benefits, Safety, Uses'. Available at: https://www.herbalreality.com/herb/witch-hazel/ Traditional / reference
    https://www.herbalreality.com/herb/witch-hazel/

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.